Vishagan's Portfolio Updates

Individual investor portfolios can sometimes offer insights into conviction plays, but they are not institutional recommendations. The pharma sector often sees volatility due to regulatory changes and product pipelines.

Conduct independent due diligence on NATCO Pharma, focusing on its current financial health, product pipeline, and market position.

For Indian markets, this story mainly matters for NATCOPHARM and the banking pocket. The current signal is bullish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Mentioned as a significant holding in an individual's portfolio, with past challenges acknowledged but not current news. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Vishagan, a senior IT consultant, shares his equity portfolio.
• •NATCO is his biggest holding.
• •Acknowledges NATCO's operating profit margin contraction in FY2022 due to Covid-19 inventory write-down and credit losses.
• •Risk flag: This is an individual's opinion, not a professional analyst's recommendation.
• •Risk flag: Past performance (FY2022) is not indicative of future results.